For the Inventor, By the Inventor

Enter assignee name

Active Biotech Ab

USPTO Granted Patents = 42

CIPO Patents = 4

EPO Patents = 17

Forward Citations = 546

Loading Chart...

Loading Chart...

73 inventors (with patents filed for the assignee):

Gunnar Hedlund (9 out of 13 patents)

Karl Erik Jansson (7 out of 13 patents)

Tomas Fex (6 out of 9 patents)

4. David Liberg (5 out of 8 patents)

5. Göran Forsberg (5 out of 7 patents)

6. Anders K Bjork (5 out of 13 patents)

7. Stephen East (4 out of 12 patents)

8. Tomas Fristedt (4 out of 6 patents)

9. Hans Wännman (4 out of 4 patents)

10. Philip Huxley (3 out of 4 patents)

11. Stig Jonsson (3 out of 5 patents)

12. Colin MacKinnon (3 out of 3 patents)

13. Helena Eriksson (3 out of 3 patents)

14. Marie Törngren (3 out of 3 patents)

15. Ingela Fritzson (3 out of 5 patents)

Core Competencies:

Tasquinimod

Ocular Inflammatory Diseases

S100-Inhibitors

Quinoline Carboxamides

Hyperproliferative Disease

Immunomodulatory Compounds

Superantigens

Cancer Treatment

Deuterium-Enriched Compounds

Chimeric Superantigens

Colon Cancer Antibodies

Target-Seeking Compounds

42 patents: Sort by Forward Citations

1. 12485095 - Plurality of tasquinimod particles and use thereof (2025-12-02),

2. 12208091 - Compounds for treatment of eye diseases associated with excessive vascularisation (2025-01-28),

3. 11654140 - Treatment of ocular inflammatory diseases using laquinimod (2023-05-23),

4. 11478465 - Compounds for treatment of eye diseases associated with excessive vascularisation (2022-10-25),

5. 10385069 - Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors (2019-08-20),

6. 10314836 - Quinoline carboxamides for use in the treatment of multiple myeloma (2019-06-11),

7. 10300053 - Quinoline carboxamides for use in the treatment of leukemia (2019-05-28),

8. 10125125 - N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors (2018-11-13),

9. 9956212 - Quinoline carboxamides for use in the treatment of multiple myeloma (2018-05-01),

10. 9873687 - N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors (2018-01-23),

11. 9771372 - Compounds useful as S100-inhibitors (2017-09-26),

12. 9216956 - Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide (2015-12-22),

13. 8871936 - Method for manufacturing of quinoline-3-carboxamides (2014-10-28),

14. 8841421 - S100A9 interaction screening method (2014-09-23),

15. 8754104 - Crystalline salts of quinoline compounds and methods for preparing them (2014-06-17),

Active Biotech AB is a biopharmaceutical company specializing in research and development of innovative pharmaceuticals. The company focuses primarily on treatments for autoimmune and inflammatory diseases, as well as cancer. Active Biotech operates globally, collaborating with partners to conduct clinical trials and bring new therapies to the market. With a strong commitment to scientific excellence, the company aims to improve the lives of patients through groundbreaking medical advancements.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

42 Patents

#14 in Lund

#156 in Sweden

#15,864 in the World

Active Biotech Ab

Forward Citations = 546

73 inventors:

Gunnar Hedlund (9 out of 13 patents)

Karl Erik Jansson (7 out of 13 patents)

Tomas Fex (6 out of 9 patents)

4. David Liberg (5 out of 8 patents)

5. Göran Forsberg (5 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…